Platinum-sensitive / platinum-resistant
Whether a cancer that responded to platinum chemotherapy came back more than six months later (sensitive, so platinum can be used again) or sooner (resistant, so something else is needed). The dividing line shapes ovarian and small-cell lung cancer treatment.
In ovarian cancer, relapse ≥6 months after platinum is treated with another platinum doublet, often followed by PARP maintenance, and secondary cytoreduction may help; relapse within 6 months (resistant) or during treatment (refractory) has response rates under 15% to single agents and is where mirvetuximab (folate receptor alpha), and trials of new ADCs, are focused. Small-cell lung cancer uses a 90-day cut-off for platinum-etoposide rechallenge. 'Platinum-ineligible' (kidney function, hearing, neuropathy) defines a treatment pathway in bladder cancer. Platinum-resistance mechanisms include restored homologous recombination (BRCA reversion) and drug efflux.
Pages like this
not linked directly; found by shared links- PairingPlatinum chemotherapy in HRD tumours
Shares Platinum agents, Carboplatin, Ovarian cancer.
- IdeaA strategic reserve of essential generic cancer drugs to end recurring shortages
Shares Platinum agents, Carboplatin.
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Platinum agents, Carboplatin.
- PathwayDouble-strand break repair: HR versus end joining
Shares Homologous recombination deficiency (HRD), Cisplatin, Platinum agents, Carboplatin.
- IdeaProtect hearing from cisplatin in adults as we now do in children
- InstitutionIndiana University Melvin and Bren Simon Comprehensive Cancer Center
Shares Cisplatin, Platinum agents.
- CancerVulvar cancer
Shares Cisplatin, Platinum agents, Carboplatin.
- TrialINTERLACE
Shares Cisplatin, Carboplatin.